KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.95

Comparing adaptive and dose redistributed radiotherapy to conventional radiotherapy in head and neck cancer - Quality of life results from the phase III ARTFORCE trial.

Anna Liza M P de Leeuw, Frank J P Hoebers, Jordi Giralt, Yungan Tao, Chris H J Terhaard, Lip Wai Lee, Signe Friesland, Roel J H M Steenbakkers, Lisa Tans, Mutamba T Kayembe, Simon R van Kranen, Harry Bartelink, Coen R N Rasch, Jan-Jakob Sonke, Olga Hamming-Vrieze

Radiother Oncol 210 111044

PMID40651596
PMCID-
DOI10.1016/j.radonc.2025.111044
发表日期2025-07-12
入排依据:This is a quality-of-life analysis from a Phase III randomized trial in head and neck cancer. While it meets criteria for oncology, human, randomized, phase 3, and original result, it is excluded because the endpoint is patient-reported quality of life, not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Additionally, the intervention is radiotherapy only (no drug-containing intervention).
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

PURPOSE: This study compared patient-reported quality of life (QoL) between patients with head and neck cancer treated with either FDG/PET-guided dose redistribution with scheduled treatment adaptation (rRT) or conventional radiotherapy (cRT). METHODS: QoL outcomes were assessed at baseline, directly after radiotherapy and at 6-month, 1-, 2-, and 5-year follow up using the EORTC QLQ C30, EORTC QLQ HN35 and EQ-5D-5L. Linear mixed-effects models (LMMs) were used for longitudinal analysis including fixed effects for baseline QoL scores, trial arm, time, an interaction term between trial arm and time and random effects for patients. RESULTS: 142 out of 221 patients (64 %) filled out at least one QoL questionnaire and were included for analysis. QoL was overall comparable between trial arms, with exception of a significant increase in sticky saliva complaints at 1 year and decreased global health status at 2 years in cRT compared to rRT. In the majority of the other LMMs, patients' QoL was significantly associated with their baseline QoL values and initial QoL deterioration observed after treatment was followed by improvement throughout follow up. CONCLUSIONS: In line with the primary results of the trial (ARTFORCE, NCT01504815), dose redistribution combined with scheduled treatment adaptation showed comparable QoL outcome to conventional radiotherapy. Overall, QoL was mostly determined by patients' individual baseline QoL and improved at 6 months of follow up. These results confirm that this dose redistribution strategy is a safe strategy to increase dose to tumor subregions.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。